Towards vaccines against human papillomavirus type-16 genital infections.
Human papillomavirus type-16 (HPV-16) is strongly associated with cervical carcinoma and cervical intraepithelial neoplasia. It may soon be possible to develop prophylactic vaccines designed to induce neutralizing antibodies to HPV-16 virions in genital secretions and therapeutic vaccines to induce cytotoxic T-cell responses against HPV-16 early proteins in cervical intraepithelial neoplasia and cervical cancers. Although significant advances have been achieved, problems remain before such vaccines can be used routinely.
Richard DimbleBy Laboratory of Cancer Virology, United Medical and Dental Schools, Rayne Institute, London, UK.
J
J
Cason
S A
SA
Khan
J M
JM
Best
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002278:Carcinoma in Situ / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D005260:Female; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000276:immunology; D027383:Papillomaviridae / Q000276:immunology* / Q000502:physiology; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014412:Tumor Virus Infections / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D002577:Uterine Cervical Diseases / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D014614:Vaccines, Synthetic / Q000276:immunology / Q000627:therapeutic use; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use; D014779:Virus Replication
D000914:Antibodies, Viral; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16